Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487695 · ClinicalTrials.gov registry record · Phase 3
Confocal Endomicroscopy for Barrett's Esophagus
A Phase 3 study of Esophageal Adenocarcinoma and Barrett's Esophagus, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00487695 is a Phase 3 study of Esophageal Adenocarcinoma and Barrett's Esophagus that has completed, run by Johns Hopkins University. The registered enrollment target is 46 participants, below the 307-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00487695, a Phase 3 study of Esophageal Adenocarcinoma and Barrett's Esophagus, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if confocal laser endomicroscopy (CLE) can improve detection of Barrett's esophagus, dysplasia, and early esophageal cancer.
Conditions Studied
Interventions
- DEVICE confocal laser endomicroscopy (CLE)
- DEVICE standard endoscopy (EGD)
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00487695
The ClinicalTrials.gov registry entry for NCT00487695 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 307-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (85% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which confocal laser endomicroscopy (CLE) is the first listed.
NCT00487695 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00487695 about?
NCT00487695 is a clinical study titled "Confocal Endomicroscopy for Barrett's Esophagus". The purpose of this study is to determine if confocal laser endomicroscopy (CLE) can improve detection of Barrett's esophagus, dysplasia, and early esophageal cancer.
What is the current status of trial NCT00487695?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2007-04. Estimated completion is 2008-09.
What conditions does trial NCT00487695 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett's Esophagus.
What interventions are being tested in trial NCT00487695?
The interventions under investigation include: confocal laser endomicroscopy (CLE) (DEVICE), standard endoscopy (EGD) (DEVICE).
Who is sponsoring clinical trial NCT00487695?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00487695 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.